Study of labetalol vs. methyldopa in treatment of pregnancy induced hypertension

Gurjar, Bhakti; Malewar, Samidha S.

doi:10.18203/2320-1770.ijrcog20192434

Cited by 3 publications

(1 citation statement)

References 17 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Safety profile of both drugs was similar. 6 In a study comparing labetalol and methyldopa labetalol receiving women showed significant drop on mean arterial pressure and showed that labetalol is safe and efficient drug of choice while treating gestational hypertension. 7 Another study declared more hypotension observed with labetalol use irrespective of dosage and use.…”

Section: Introductionmentioning

confidence: 99%

Oral Labetalol in Comparison with Methyldopa in Treatment of Gestational Hypertension as a First Line Drug

Akhter¹,

Hashmi²,

Kaynat³

et al. 2023

PJMHS

View full text Add to dashboard Cite

Background: Defining hypertension in pregnancy, it is taken as systolic blood pressure of 140 or more and diastolic blood pressure of 90mg or more. Presence of proteinurea differentiates chronic hypertension and gestational hypertension from pre eclampsia .Prevalence and incidence of hypertension in pregnancy along with its complications like end-organ damage, preeclampsia, eclampsia, and postpartum eclampsia are increasing. Gestational hypertension and its sequels are major causes of fetal and maternal morbidity and mortality and affect almost 8% of pregnancies. Labetalol and methyldopa were effective in reducing systolic and diastolic BP significantly but labetalol was found to control BP more rapidly and efficiently. Safety profile of both drugs was similar. The rationale of this study is Labetalol is more effective in comparison with Methyldopa in pregnancy induced hypertensive females in terms of control of blood pressure within 48hours of drug intake, in pregnant patients between POG of 28 to 32 weeks. Design: Randomized control trial. Place and Duration of Study: Department of Gynaecology Unit 2 Bahawal Victoria Hospital, Bahawalpur from 1st January 2022 to 31st December 2022. Methodology: One hundred 100 patients having gestational hypertension between periods of gestation from 28to 32 weeks were enrolled. They were divided into 2 groups; group A treated with labetalol and B treated with methyldopa respectively. Results: Statistical no significant difference in systolic and diastolic blood pressure was observed before starting treatment in both groups but a significant fall in diastolic blood pressure was observed in group A after 48 hrs of initiation of treatment i.e., with labetalol (P = 0.007) Conclusion: Both labetalol and methyldopa reduce blood pressure in women with gestational hypertension but labetalol is more effective than methyldopa as proved by our study. Keywords: Gestational hypertension, Diastolic blood pressure, Labetalol, Methyldopa

show abstract

Section: Introductionmentioning

confidence: 99%

Oral Labetalol in Comparison with Methyldopa in Treatment of Gestational Hypertension as a First Line Drug

Akhter¹,

Hashmi²,

Kaynat³

et al. 2023

PJMHS

View full text Add to dashboard Cite

show abstract

Effect of labetalol for treating patients with pregnancy-induced hypertension: A systematic review

Bej¹,

Das²

2022

J Pract Cardiovasc Sci

View full text Add to dashboard Cite

Pregnancy-Induced Hypertension Pathophysiology and Contemporary Management Strategies: A Narrative Review

Agarwal,

Agrawal,

Singhal

et al. 2024

Cureus

View full text Add to dashboard Cite

In the case of PIH, the history is the story of gradually developing awareness and the gradual formation of requisite knowledge. The development of the sphygmomanometer, or blood pressure cuff, in the late 1700s, provided the basis for modern systematic blood pressure reporting for Gravid patients. In the following years and over a few decades, the relationship between high blood pressure and these complications, such as preeclampsia and eclampsia, became clearer. The hypertensive disease was categorized by the American Committee on Maternal Welfare in 1952, which included PIH, chronic hypertension, and preeclampsia. Today, attention is being paid to the identification of such factors, the search for ways to enhance the treatment of diseases, methods for their diagnosis, and the enhancement of pregnancy outcomes. Pregnancy can cause high blood pressure in two of the following ways: preeclampsia and gestational hypertension. These conditions are both part of something called pregnancy-induced hypertension (PIH). In the world, most problems for moms and babies during pregnancy come from PIH. To help both mom and baby, we need to know a lot about what causes it, how to manage it, and how to watch the baby carefully. Aspects like immune responses, the environment, and genes all mix to cause PIH. They make the placenta not work right. When the cells that help the placenta grow don't do their job well, when blood vessels are stiff, when there's too much stress on the body, or when there's not a good balance of chemicals that help build blood vessels, things can get bad. Blood vessels all over the body squeeze tight, blood flow goes down, and blood pressure goes up. That can make a lot of organs stop working right and stop the baby from healthy growth. Various studies concluded that PIH severely limits the blood flow to the placenta and thus contributes to reduced fetal growth. It showed that compared to other hospitals, women who experience PIH are more likely to give birth early before the baby is ready, that is, before 37 weeks, and may cause further health complications to the baby. This normally makes the offspring have low birth weight and exposes them to many complications in infancy and the future in case they are born to mothers with PIH. In severe cases, PIH may lead to the death of the infant either by stillbirth or immediately after birth. The researchers have noted several predisposing factors to PIH, which include histories of elevated blood pressure, diabetes, being overweight or obese, and having a family history of PIH. Educating women about the presence of PIH and its causes can help them consult health facilities early, thus helping leaders in achieving better pregnancy results.

show abstract

Study of labetalol vs. methyldopa in treatment of pregnancy induced hypertension

Cited by 3 publications

References 17 publications

Oral Labetalol in Comparison with Methyldopa in Treatment of Gestational Hypertension as a First Line Drug

Oral Labetalol in Comparison with Methyldopa in Treatment of Gestational Hypertension as a First Line Drug

Effect of labetalol for treating patients with pregnancy-induced hypertension: A systematic review

Pregnancy-Induced Hypertension Pathophysiology and Contemporary Management Strategies: A Narrative Review

Contact Info

Product

Resources

About